Core Viewpoint - A shareholder has filed a securities class action lawsuit against ImmunityBio, Inc. for alleged misrepresentations regarding its lead biologic product, ANKTIVA, affecting investors who purchased securities between January 19, 2026, and March 24, 2026 [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements about the capabilities of ANKTIVA, which is the company's primary biologic product [4]. - Investors who acquired ImmunityBio securities during the specified period are eligible to join the class action [1][2]. - The deadline to file as a lead plaintiff is May 26, 2026, and participation does not require serving as a lead plaintiff [3]. Group 2: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders will not incur any fees or expenses unless there is a recovery [3][5]. - The firm has a strong track record, having recovered over $3.5 billion for clients and being recognized multiple times in legal industry rankings [5].

Core Viewpoint - Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Pinterest, Inc. (NYSE: PINS) securities between February 7, 2025, and February 12, 2026, alleging that the company misled investors regarding its advertising revenues [1][2]. Allegations - The lawsuit claims that Pinterest failed to disclose significant issues affecting its advertising revenues, including reduced revenues from advertising partners and the impact of U.S. tariffs on its business operations [2]. - It is alleged that Pinterest overstated its ability to manage these macroeconomic challenges, leading to misleading public statements about its financial health [2]. Financial Performance - On February 12, 2026, Pinterest reported quarterly revenue of $1.32 billion, which was below the consensus estimate of $1.33 billion. The company also provided Q1 2026 revenue guidance of $951 million to $971 million, falling short of the consensus estimate of $980.6 million [3]. - CEO William Ready attributed the company's performance to "exogenous shock" related to tariffs, which disproportionately affected advertising spending from top retail advertisers. CFO Julia Donnelly indicated that these tariff-related headwinds are expected to continue and may worsen in Q1 [3]. Stock Impact - Following the announcement of disappointing financial results, Pinterest's stock price dropped by $3.12 per share, or 16.83%, closing at $15.42 on February 13, 2026 [3].

SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegat ...

Core Viewpoint - Robbins LLP has announced a class action lawsuit against Vital Farms, Inc. for allegedly misleading investors regarding its business prospects during the period from May 8, 2025, to February 26, 2026 [1][2]. Allegations - The lawsuit claims that Vital Farms made false and misleading statements about the implementation of an enterprise resource planning (ERP) system, which was said to be crucial for operational improvements [2]. - Defendants allegedly did not disclose that the ERP implementation would lead to delays in shipments and production, which could negatively impact the company's business [2]. - The complaint highlights that management was aware of potential issues surrounding the ERP implementation but failed to adequately inform investors [2]. Financial Performance - On February 26, 2026, Vital Farms reported its fiscal year 2025 revenue at $759.44 million, which was below the guidance of $775 million [3]. - The company also reported earnings per share (EPS) of $0.35, missing the market consensus of $0.39 [3]. - Following the release of this information, Vital Farms' stock price fell by $2.68, or 10.8%, closing at $22.11 [3]. Class Action Participation - Shareholders who purchased Vital Farms securities during the specified period may be eligible to participate in the class action lawsuit [4]. - Interested parties can contact Robbins LLP to serve as lead plaintiff or to receive further information [4]. Company Background - Vital Farms is recognized as a leading U.S. brand of pasture-raised eggs and the second-largest U.S. egg brand by retail dollar sales [1].

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. for allegedly misleading investors about its lead product, Anktiva, during the specified class period from January 19, 2026, to March 25, 2026 [1][2]. Allegations - The complaint claims that Soon-Shiong, a defendant in the case, materially overstated the capabilities of Anktiva, which is intended for treating a specific type of bladder cancer [2]. - A warning letter from the U.S. Food and Drug Administration (FDA) was publicized on March 24, 2026, indicating that promotional communications created a misleading impression that Anktiva could cure and prevent all cancers [3]. Market Impact - Following the release of the FDA warning letter, ImmunityBio's stock price fell by $1.98 per share, representing a 21% decline, closing at $7.42 per share on March 24, 2026 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by May 26, 2026. Participation in the case is not required to be eligible for recovery [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. for allegedly misleading investors about its lead product candidate, Anktiva, during the period from January 19, 2026, to March 25, 2026 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Soon-Shiong, the defendant, materially overstated Anktiva's capabilities, leading to misleading impressions about its effectiveness [2]. - A warning letter from the U.S. Food and Drug Administration (FDA) was publicized on March 24, 2026, indicating that promotional communications created a misleading impression that Anktiva could cure and prevent all cancer [3]. - Following the FDA warning, ImmunityBio's stock price fell by $1.98 per share, or 21%, closing at $7.42 per share on March 24, 2026 [3]. Group 2: Legal Proceedings and Participation - Shareholders who wish to participate in the class action can contact Robbins LLP, and those interested in serving as lead plaintiffs are encouraged to reach out [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - ImmunityBio, Inc. is a biotechnology company, with Anktiva being its lead biologic product aimed at treating a specific type of bladder cancer [1].

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences [1] - Elon Musk predicts that humanoid robots could create a market worth $250 trillion by 2040, representing a major shift in the global economy driven by AI innovation [2] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a significant advancement with the potential for substantial social benefits [8] - The article suggests that investors may regret not owning shares in a specific AI company that is positioned to capitalize on this technological wave [9]

Core Insights - Robinhood Markets has evolved into a diversified financial platform, achieving record total net sales of $4.5 billion in 2025, indicating its significance in the financial ecosystem for the next generation [1] - As of February 2026, Robinhood reported total assets of $314.2 billion, a 68% increase year-over-year, with funded customers reaching 27.4 million and net deposits hitting a record $68 billion, reflecting a 36% annual growth rate [2] - The company is focusing on three main pillars: Advanced Trading, Predictive Markets, and AI Integration, following its acquisition of a majority stake in MIAXdx, which has expanded its prediction markets business [3] Company Developments - Robinhood is enhancing its Legend platform with advanced tools such as futures, options, and professional-grade charting to attract experienced traders, leading to growth in margin lending balances and interest-earning assets [4] - AI-driven tools like Cortex are providing real-time insights into market activity, helping users understand complex data and empowering them with actionable analysis [4] Stock Analysis Methodology - The selection of stocks under $10 on the Robinhood app is based on recent noteworthy developments likely to influence investor sentiment, with a focus on stocks popular among analysts and hedge funds [7] - Research indicates that mimicking top hedge fund stock picks can lead to market outperformance, with a reported return of 498.7% since May 2014, significantly beating benchmarks [8] Featured Stocks - Health Catalyst, Inc. (NASDAQ:HCAT) has a share price of $1.17 and is facing challenges, with Wells Fargo lowering its rating and price target due to anticipated revenue and margin issues [10][11] - HCAT's estimated revenue for Q1 2026 is projected between $68 million and $70 million, with Adjusted EBITDA expected between $7 million and $8 million, as the company focuses on long-term execution improvements [12][13] - ImmunityBio, Inc. (NASDAQ:IBRX) has a share price of $8.56 and received a Buy rating from BTIG, with a price target of $13, supported by strong sales growth and recent advancements in its therapy platform [15][16] - IBRX has completed significant manufacturing engineering programs and reported positive results from a Phase 1 study, indicating progress in its immunotherapy development [17][18]

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that humanoid robots could create a market worth $250 trillion by 2040, representing a major shift in the global economy driven by AI innovation [2] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is believed to be redefining work, learning, and creativity, attracting significant interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4] - Prominent investors, including Bill Gates and Warren Buffett, recognize AI as a major technological advancement with the potential for substantial social benefits [8] Market Opportunity - The anticipated $250 trillion market is not limited to a single company but encompasses an entire ecosystem of AI innovators, indicating a vast opportunity for growth and investment [2] - The narrative suggests that investors may soon regret not owning shares in a specific AI company that is positioned to capitalize on this technological wave [9]

Core Viewpoint - ImmunityBio Inc. has successfully completed its manufacturing engineering programs for its NK cell therapy platform, leading to a significant increase in its stock price. Group 1: NK Cell Therapy Development - The company has completed its NK2022 and NK2023 programs, which assessed the safety and reproducibility of its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy [1][2] - A total of 64 subjects participated in the trials, with no serious adverse events reported, demonstrating the safety of the therapy [2] - ImmunityBio can generate up to five billion NK cells from a single apheresis collection, allowing for the production of eight to ten therapeutic doses within 12 days [2][4] Group 2: Management Insights - Patrick Soon-Shiong, the founder and executive chairman, stated that the data shows the potential for scalable and safe manufacturing of NK cell therapy, which could provide a reliable source of potent NK cells [3] - The concept of creating a "World Bank of Natural Killer Cells" was introduced, suggesting that NK cells could be universally donated without HLA matching [4] Group 3: Regulatory Developments - The FDA has acknowledged receipt of ImmunityBio's supplemental Biologics License Application (sBLA) for ANKTIVA, aimed at treating BCG-unresponsive non-muscle invasive bladder cancer [5] - The resubmission follows ongoing discussions with the FDA that began in January 2026, with additional efficacy data submitted in March [5] Group 4: Analyst Consensus and Stock Performance - The stock currently holds a Buy rating with an average price target of $12.57, reflecting positive analyst sentiment [6] - Recent analyst actions include a Buy rating from BTIG with a target of $13 and D. Boral Capital maintaining a target of $23 [6] - ImmunityBio shares rose by 10.60% to $8.65 at the time of publication [6]